Chen K, et al. - The role of Galectin-1 in neuroblastoma biomonitoring therapy was examined in this analysis. To assess the relationship between Galectin-1 expression and clinical features, a tissue microarray containing thirty-seven neuroblastoma tissue samples were used. Researchers conducted Kaplan–Meier analysis and ROC analysis to distinguish the outcome correlated with high or low expression of Galectin-1 in patients with neuroblastoma. In patients with neuroblastoma, tissue and serum Galectin-1 levels were correlated with adverse clinical features. The findings from the present study suggested that serum Galectin-1 (sGalectin-1) could be a potential biomarker for monitoring therapy.